Central nicotinic receptors, neurotrophic factors and neuroprotection

Behavioural Brain Research

Volumn 113, Issue 1-2, 2000, Pages 21-34

  Belluardo, Natale ^a,b   Mudò, Giuseppa ^b   Blum, Mariann ^c   Fuxe, Kjell ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

FGF 2; nAChR; Neuroprotection; Neurotrophic factors

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR AFFECTING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; EPIBATIDINE; FIBROBLAST GROWTH FACTOR; NEUROTROPHIC FACTOR; NICOTINE; NICOTINIC RECEPTOR; RECEPTOR SUBUNIT;

ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; BRAIN; CELL SURVIVAL; FIBROBLAST GROWTH FACTOR 2; HAPLORHINI; HUMANS; NERVE GROWTH FACTORS; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RECEPTORS, NICOTINIC;

EID: 0033846277     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00197-2     Document Type: Article

References (170)

1. Akaike A., Tamura Y., Yokota T., Shimohama S., Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644:1994;181-187.
2. Anderson K.J., Dam D., Lee S., Cotman C.W. Basic fibroblast growth factor prevents death of lesioned cholinergic neurons in vivo. Nature. 332:1988;360-361.
3. Arendash G.W., Sengstock G.J., Sanberg P.R., Kem W.R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674:1995;252-259.
4. Arias H.R. Topology of ligand binding sites on the nicotinic acetylcholine receptor. Brain Res. Brain Res. Rev. 25:1997;133-191.
5. Arneric S.P., Sullivan J.P., Briggs C.A., Donnelly-Roberts D., Anderson D.J., Raszkiewicz J.L., Hughes M.L., Cadman E.D., Adams P., Garvey D.S. et al. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. in vitro characterization. J. Pharmacol. Exp. Ther. 270:1994;310-318.
6. Badio B., Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45:1994;563-569.
7. Baird A. Fibroblast growth factors: activities and significance of non-neurotrophin neurotrophic growth factors. Curr. Opin. Neurobiol. 4:1994;78-86.
8. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., Arneric S.P. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 279:1998;77-81.
9. Barde Y.A. Trophic factors and neuronal survival. Neuron. 2:1989;1525-1534.
10. Baron J.A. Cigarette smoking and Parkinson's disease. Neurology. 36:1986;1490-1496.
11. Baumann R.J., Jameson H.D., McKean H.E., Haack D.G., Weisberg L.M. Cigarette smoking and Parkinson disease: 1. comparison of cases with matched neighbors. Neurology. 30:1980;839-843.
12. Belluardo N., Blum M., Mudo G., Andbjer B., Fuxe K. Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat. Neuroscience. 83:1998;723-740.
13. Belluardo N., Mudo G., Blum M., Cheng Q., Caniglia G., Dell'Albani P., Fuxe K. The nicotinic acetylcholine receptor agonist (+/-)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain [in process citation]. Brain Res. Mol. Brain Res. 74:1999;98-110.
14. Belluardo N., Mudo G., Caniglia G., Cheng Q., Fuxe K. The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 10:2000;3909-3913.
15. Belluardo N., Wu G., Mudo G., Hansson A.C., Pettersson R., Fuxe K. Comparative localization of fibroblast growth factor receptor-1, -2, and -3 mRNAs in the rat brain: in situ hybridization analysis. J. Comp. Neurol. 379:1997;226-246.
16. Bencherif M., Schmitt J.D., Bhatti B.S., Crooks P., Caldwell W.S., Lovette M.E., Fowler K., Reeves L., Lippiello P.M. The heterocyclic substituted pyridine derivative (+/-)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 284:1998;886-894.
17. Bertrand D., Galzi J.L., Devillers-Thiery A., Bertrand S., Changeux J.P. Stratification of the channel domain in neurotransmitter receptors. Curr. Opin. Cell Biol. 5:1993;688-693.
18. Blum M., Wu G., Mudo G., Belluardo N., Andersson K., Agnati L.F., Fuxe K. Chronic continuous infusion of (-)nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6-hydroxydopamine-lesioned rat. Neuroscience. 70:1996;169-177.
19. Borlongan C.V., Shytle R.D., Ross S.D., Shimizu T., Freeman T.B., Cahill D.W., Sanberg P.R. nicotine protects against systemic kainic acid-induced excitotoxic effects. Exp. Neurol. 136:1995;261-265.
20. Briggs C.A., Anderson D.J., Brioni J.D., Buccafusco J.J., Buckley M.J., Campbell J.E., Decker M.W., Donnelly-Roberts D., Elliott R.L., Gopalakrishnan M., Holladay M.W., Hui Y.H., Jackson W.J., Kim D.J., Marsh K.C., O'Neill A., Prendergast M.A., Ryther K.B., Sullivan J.P., Arneric S.P. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 57:1997;231-241.
21. Briggs C.A., McKenna D.G., Piattoni-Kaplan M. Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology. 34:1995;583-590.
22. Chadi G., Cao Y., Pettersson R.F., Fuxe K. Temporal and spatial increase of astroglial basic fibroblast growth factor synthesis after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine neurons. Neuroscience. 61:1994;891-910.
23. Chadi G., Moller A., Rosen L., Janson A.M., Agnati L.A., Goldstein M., Ogren S.O., Pettersson R.F., Fuxe K. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp. Brain Res. 97:1993;145-158.
24. Changeux J.P., Bertrand D., Corringer P.J., Dehaene S., Edelstein S., Lena C., Le Novere N., Marubio L., Picciotto M., Zoli M. Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res. Brain Res. Rev. 26:1998;198-216.
25. Cheng B., Mattson M.P. NGF and bFGF protect rat hippocampal and human cortical neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron. 7:1991;1031-1041.
26. Connor B., Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Brain Res. Rev. 27:1998;1-39.
27. Conroy W.G., Berg D.K. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J. Biol. Chem. 270:1995;4424-4431.
28. Conroy W.G., Vernallis A.B., Berg D.K. The alpha 5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron. 9:1992;679-691.
29. Couturier S., Bertrand D., Matter J.M., Hernandez M.C., Bertrand S., Millar N., Valera S., Barkas T., Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron. 5:1990;847-856.
30. Cucina A., Corvino V., Sapienza P., Borrelli V., Lucarelli M., Scarpa S., Strom R., Santoro D.A.L., Cavallaro A. Nicotine regulates basic fibroblastic growth factor and transforming growth factor beta1 production in endothelial cells. Biochem. Biophys. Res. Commun. 257:1999;306-312.
31. Date I., Yoshimoto Y., Imaoka T., Miyoshi Y., Gohda Y., Furuta T., Asari S., Ohmoto T. Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging. Brain Res. 621:1993;150-154.
32. Decker M.W., Brioni J.D., Bannon A.W., Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 56:1995;545-570.
33. Decker M.W., Brioni J.D., Sullivan J.P., Buckley M.J., Radek R.J., Raszkiewicz J.L., Kang C.H., Kim D.J., Giardina W.J., Wasicak J.T. et al. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. in vivo characterization. J. Pharmacol. Exp. Ther. 270:1994;319-328.
34. Decker M.W., Curzon P., Brioni J.D., Arneric S.P. Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats. Eur. J. Pharmacol. 261:1994;217-222.
35. Decker M.W., Majchrzak M.J., Anderson D.J. Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res. 572:1992;281-285.
36. Dionne C.A., Crumley G., Bellot F., Kaplow J.M., Searfoss G., Ruta M., Burgess W.H., Jaye M., Schlessinger J. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J. 9:1990;2685-2692.
37. Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Piattoni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. in vitro characterization. J. Pharmacol. Exp. Ther. 285:1998;777-786.
38. Donnelly-Roberts D.L., Xue I.C., Arneric S.P., Sullivan J.P. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res. 719:1996;36-44.
39. Dono R., Texido G., Dussel R., Ehmke H., Zeller R. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J. 17:1998;4213-4225.
40. Elgoyhen A.B., Johnson D.S., Boulter J., Vetter D.E., Heinemann S. Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell. 79:1994;705-715.
41. Ernfors P., Lonnerberg P., Ayer-LeLievre C., Persson H. Developmental and regional expression of basic fibroblast growth factor mRNA in the rat central nervous system. J. Neurosci. Res. 27:1990;10-15.
42. Ferrari G., Minozzi M.C., Toffano G., Leon A., Skaper S.D. Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev. Biol. 133:1989;140-147.
43. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41:1992;31-37.
44. Florkiewicz R.Z., Sommer A. Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons [published erratum appears in Proc Natl Acad Sci USA 1990 Mar;87(5):2045]. Proc. Natl. Acad. Sci. USA. 86:1989;3978-3981.
45. Forsayeth J.R., Kobrin E. Formation of oligomers containing the beta3 and beta4 subunits of the rat nicotinic receptor. J. Neurosci. 17:1997;1531-1538.
46. Freedman R., Wetmore C., Stromberg I., Leonard S., Olson L. Alpha-bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth factor expression. J. Neurosci. 13:1993;1965-1975.
47. Freese A., Finklestein S.P., DiFiglia M. Basic fibroblast growth factor protects striatal neurons in vitro from NMDA-receptor mediated excitotoxicity. Brain Res. 575:1992;351-355.
48. French S.J., Humby T., Horner C.H., Sofroniew M.V., Rattray M. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Brain Res. Mol. Brain Res. 67:1999;124-136.
49. Fuxe K., Janson A.M., Jansson A., Andersson K., Eneroth P., Agnati L.F. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn Schmiedebergs Arch. Pharmacol. 341:1990;171-181.
50. Fuxe K., Tinner B., Zoli M., Pettersson R.F., Baird A., Biagini G., Chadi G., Agnati L.F. Computer-assisted mapping of basic fibroblast growth factor immunoreactive nerve cell populations in the rat brain. J. Chem. Neuroanat. 11:1996;13-35.
51. Gall C.M., Berschauer R., Isackson P.J. Seizures increase basic fibroblast growth factor mRNA in adult rat forebrain neurons and glia. Brain Res. Mol. Brain Res. 21:1994;190-205.
52. Gao Z.G., Cui W.Y., Zhang H.T., Liu C.G. Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine- induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice. Pharmacol. Res. 38:1998;101-106.
53. Gensburger C., Labourdette G., Sensenbrenner M. Brain basic fibroblast growth factor stimulates the proliferation of rat neuronal precursor cells in vitro. FEBS Lett. 217:1987;1-5.
54. Gerzanich V., Anand R., Lindstrom J. Homomers of alpha 8 and alpha 7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties. Mol. Pharmacol. 45:1994;212-220.
55. Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., Lindstrom J. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 48:1995;774-782.
56. Giacobini E. Cholinergic receptors in human brain: effects of aging and Alzheimer disease. J. Neurosci. Res. 27:1990;548-560.
57. Giordano S., Sherman L., Lyman W., Morrison R. Multiple molecular weight forms of basic fibroblast growth factor are developmentally regulated in the central nervous system. Dev. Biol. 152:1992;293-303.
58. Godwin-Austen R.B., Lee P.N., Marmot M.G., Stern G.M. Smoking and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 45:1982;577-581.
59. Gomez-Pinilla F., Lee J.W., Cotman C.W. Basic FGF in adult rat brain: cellular distribution and response to entorhinal lesion and fimbria-fornix transection. J. Neurosci. 12:1992;345-355.
60. Gonzalez A.M., Berry M., Maher P.A., Logan A., Baird A. A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain. Brain. Res. 701:1995;201-226.
61. Grothe C., Otto D., Unsicker K. Basic fibroblast growth factor promotes in vitro survival and cholinergic development of rat septal neurons: comparison with the effects of nerve growth factor. Neuroscience. 31:1989;649-661.
62. Hefti F. Is Alzheimer disease caused by lack of nerve growth factor? Ann. Neurol. 13:1983;109-110.
63. Hellstrom-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res. Mol. Brain Res. 66:1999;94-103.
64. Hill J.A. Jr, Zoli M., Bourgeois J.P., Changeux J.P. Immunocytochemical localization of a neuronal nicotinic receptor: the beta 2-subunit. J. Neurosci. 13:1993;1551-1568.
65. Huber K., Meisinger C., Grothe C. Expression of fibroblast growth factor-2 in hypoglossal motoneurons is stimulated by peripheral nerve injury. J. Comp. Neurol. 382:1997;189-198.
66. Humpel C., Lippoldt A., Chadi G., Ganten D., Olson L., Fuxe K. Fast and widespread increase of basic fibroblast growth factor messenger RNA and protein in the forebrain after kainate-induced seizures. Neuroscience. 57:1993;913-922.
67. Janson A.M., Fuxe K., Agnati L.F., Kitayama I., Harfstrand A., Andersson K., Goldstein M. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res. 455:1988;332-345.
68. Janson A.M., Fuxe K., Sundstrom E., Agnati L.F., Goldstein M. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol. Scand. 132:1988;589-591.
69. Janson A.M., Hedlund P.B., Fuxe K., von Euler G. Chronic nicotine treatment counteracts dopamine D2 receptor upregulation induced by a partial meso-diencephalic hemitransection in the rat. Brain Res. 655:1994;25-32.
70. Janson A.M., Meana J.J., Goiny M., Herrera-Marschitz M. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study. Neurosci. Lett. 134:1991;88-92.
71. Janson A.M., Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience. 57:1993;931-941.
72. Johnson E.M. Jr, Chang J.Y., Koike T., Martin D.P. Why do neurons die when deprived of trophic factor? Neurobiol. Aging. 10:1989;549-552.
73. Jones G.M., Sahakian B.J., Levy R., Warburton D.M., Gray J.A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl.). 108:1992;485-494.
74. Kamiguchi H., Yoshida K., Wakamoto H., Inaba M., Sasaki H., Otani M., Toya S. Cytokine-induced selective increase of high-molecular-weight bFGF isoforms and their subcellular kinetics in cultured rat hippocampal astrocytes. Neurochem. Res. 21:1996;701-706.
75. Kaneko S., Maeda T., Kume T., Kochiyama H., Akaike A., Shimohama S., Kimura J. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res. 765:1997;135-140.
76. Keegan K., Johnson D.E., Williams L.T., Hayman M.J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc. Natl. Acad. Sci. USA. 88:1991;1095-1099.
77. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
78. Kihara T., Shimohama S., Urushitani M., Sawada H., Kimura J., Kume T., Maeda T., Akaike A. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res. 792:1998;331-334.
79. Kiyota Y., Takami K., Iwane M., Shino A., Miyamoto M., Tsukuda R., Nagaoka A. Increase in basic fibroblast growth factor-like immunoreactivity in rat brain after forebrain ischemia. Brain Res. 545:1991;322-328.
80. Knusel B., Michel P.P., Schwaber J.S., Hefti F. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J. Neurosci. 10:1990;558-570.
81. Kumon Y., Sakaki S., Kadota O., Matsuda S., Fujita H., Yoshimura H., Sakanaka M. Transient increase in endogenous basic fibroblast growth factor in neurons of ischemic rat brains. Brain Res. 605:1993;169-174.
82. Lange K.W., Wells F.R., Jenner P., Marsden C.D. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J. Neurochem. 60:1993;197-203.
83. Lapchak P.A., Araujo D.M., Hefti F. Cholinergic regulation of hippocampal brain-derived neurotrophic factor mRNA expression: evidence from lesion and chronic cholinergic drug treatment studies. Neuroscience. 52:1993;575-585.
84. Le Novere N., Changeux J.P. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J. Mol. Evol. 40:1995;155-172.
85. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology (Berl.). 108:1992;417-431.
86. Levin E.D., Christopher N.C., Briggs S.J., Rose J.E. Chronic nicotine reverses working memory deficits caused by lesions of the fimbria or medial basalocortical projection. Brain Res. Cogn. Brain Res. 1:1993;137-143.
87. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl.). 138:1998;217-230.
88. Li Y., Papke R.L., He Y.J., Millard W.J., Meyer E.M. Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells. Brain Res. 830:1999;218-225.
89. Lindstrom J., Schoepfer R., Whiting P. Molecular studies of the neuronal nicotinic acetylcholine receptor family. Mol. Neurobiol. 1:1987;281-337.
90. Lippoldt A., Andbjer B., Gerst H., Ganten D., Fuxe K. Basic fibroblast growth factor expression and tenascin C immunoreactivity after partial unilateral hemitransection of the rat brain. Brain Res. 730:1996;1-16.
91. Lippoldt A., Andbjer B., Rosen L., Richter E., Ganten D., Cao Y., Pettersson R.F., Fuxe K. Photochemically induced focal cerebral ischemia in rat: time dependent and global increase in expression of basic fibroblast growth factor mRNA. Brain Res. 625:1993;45-56.
92. Listerud M., Brussaard A.B., Devay P., Colman D.R., Role L.W. Functional contribution of neuronal AChR subunits revealed by antisense oligonucleotides [published erratum appears in Science 1992 Jan 3;255(5040):12]. Science. 254:1991;1518-1521.
93. Liu Z., D'Amore P.A., Mikati M., Gatt A., Holmes G.L. Neuroprotective effect of chronic infusion of basic fibroblast growth factor on seizure-associated hippocampal damage. Brain Res. 626:1993;335-338.
94. Lloyd G.K., Menzaghi F., Bontempi B., Suto C., Siegel R., Akong M., Stauderman K., Velicelebi G., Johnson E., Harpold M.M., Rao T.S., Sacaan A.I., Chavez-Noriega L.E., Washburn M.S., Vernier J.M., Cosford N.D., McDonald L.A. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 62:1998;1601-1606.
95. Luetje C.W., Patrick J. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J. Neurosci. 11:1991;837-845.
96. Maggio R., Riva M., Vaglini F., Fornai F., Molteni R., Armogida M., Racagni G., Corsini G.U. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem. 71:1998;2439-2446.
97. Marin P., Maus M., Desagher S., Glowinski J., Premont J. Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuroreport. 5:1994;1977-1980.
98. Martin E.J., Panickar K.S., King M.A., Deyrup M., Hunter B.E., Wang G., Meyer E.M. Cytoprotective action of 2,4,-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic neurons. Drug Dev. Res. 31:1994;135-141.
99. Mattson M.P., Murrain M., Guthrie P.B., Kater S.B. Fibroblast growth factor and glutamate: opposing roles in the generation and degeneration of hippocampal neuroarchitecture. J. Neurosci. 9:1989;3728-3740.
100. Mayer E., Dunnett S.B., Fawcett J.W. Mitogenic effect of basic fibroblast growth factor on embryonic ventral mesencephalic dopaminergic neurone precursors. Brain Res. Dev. Brain Res. 72:1993;253-258.
101. Meisinger C., Grothe C. Differential regulation of fibroblast growth factor (FGF)-2 and FGF receptor 1 mRNAs and FGF-2 isoforms in spinal ganglia and sciatic nerve after peripheral nerve lesion. J. Neurochem. 68:1997;1150-1158.
102. Messi M.L., Renganathan M., Grigorenko E., Delbono O. Activation of alpha7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons. FEBS Lett. 411:1997;32-38.
103. Meyer E.M., King M.A., Meyers C. Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Res. 786:1998;252-254.
104. Meyer E.M., Kuryatov A., Gerzanich V., Lindstrom J., Papke R.L. Analysis of 3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors. J. Pharmacol. Exp. Ther. 287:1998;918-925.
105. Minana M.D., Montoliu C., Llansola M., Grisolia S., Felipo V. Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology. 37:1998;847-857.
106. Miyamoto O., Itano T., Fujisawa M., Tokuda M., Matsui H., Nagao S., Hatase O. Exogenous basic fibroblast growth factor and nerve growth factor enhance sprouting of acetylcholinesterase positive fibers in denervated rat hippocampus. Acta Med. Okayama. 47:1993;139-144.
107. Moffett J., Kratz E., Stachowiak M.K. Increased tyrosine phosphorylation and novel cis-acting element mediate activation of the fibroblast growth factor-2 (FGF-2) gene by nicotinic acetylcholine receptor. New mechanism for trans-synaptic regulation of cellular development and plasticity. Brain Res. Mol. Brain Res. 55:1998;293-305.
108. Monteggia L.M., Arneric S.P., Giordano T. Nicotine effects on the regulation of amyloid precursor protein splicing, neurotrophin and glucose transporter RNA levels in aged rats. Int. J. Dev. Neurosci. 12:1994;133-141.
109. Morens D.M., Grandinetti A., Reed D., White L.R., Ross G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 45:1995;1041-1051.
110. Morrison R.S., Sharma A., de Vellis J., Bradshaw R.A. Basic fibroblast growth factor supports the survival of cerebral cortical neurons in primary culture. Proc. Natl. Acad. Sci. USA. 83:1986;7537-7541.
111. Nakata N., Kato H., Kogure K. Protective effects of basic fibroblast growth factor against hippocampal neuronal damage following cerebral ischemia in the gerbil. Brain Res. 605:1993;354-356.
112. Nanri M., Kasahara N., Yamamoto J., Miyake H., Watanabe H. GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn. J. Pharmacol. 74:1997;285-289.
113. Nanri M., Yamamoto J., Miyake H., Watanabe H. Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Jpn. J. Pharmacol. 76:1998;23-29.
114. Navarro H.A., Seidler F.J., Eylers J.P., Baker F.E., Dobbins S.S., Lappi S.E., Slotkin T.A. Effects of prenatal nicotine exposure on development of central and peripheral cholinergic neurotransmitter systems. Evidence for cholinergic trophic influences in developing brain. J. Pharmacol. Exp. Ther. 251:1989;894-900.
115. Newhouse P.A., Potter A., Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging. 11:1997;206-228.
116. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 4:1992;303-328.
117. Ortega S., Ittmann M., Tsang S.H., Ehrlich M., Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc. Natl. Acad. Sci. USA. 95:1998;5672-5677.
118. Otto D., Frotscher M., Unsicker K. Basic fibroblast growth factor and nerve growth factor administered in gel foam rescue medial septal neurons after fimbria fornix transection. J. Neurosci. Res. 22:1989;83-91.
119. Otto D., Unsicker K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J. Neurosci. 10:1990;1912-1921.
120. Owman C., Fuxe K., Janson A.M., Kahrstrom J. Chronic nicotine treatment eliminates asymmetry in striatal glucose utilization following unilateral transection of the mesostriatal dopamine pathway in rats. Neurosci. Lett. 102:1989;279-283.
121. Owman C., Fuxe K., Janson A.M., Kahrstrom J. Studies of protective actions of nicotine on neuronal and vascular functions in the brain of rats: comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber systems, and the effect of a dopamine agonist. Prog. Brain Res. 79:1989;267-276.
122. Partanen J., Makela T.P., Eerola E., Korhonen J., Hirvonen H., Claesson-Welsh L., Alitalo K. FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J. 10:1991;1347-1354.
123. Peeke S.C., Peeke H.V. Attention, memory, and cigarette smoking. Psychopharmacology (Berl.). 84:1984;205-216.
124. Perry D.C., Davila-Garcia M.I., Stockmeier C.A., Kellar K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289:1999;1545-1552.
125. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
126. Picciotto M.R., Zoli M., Lena C., Bessis A., Lallemand Y., LeNovere N., Vincent P., Pich E.M., Brulet P., Changeux J.P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature. 374:1995;6565-6567.
127. Prats H., Kaghad M., Prats A.C., Klagsbrun M., Lelias J.M., Liauzun P., Chalon P., Tauber J.P., Amalric F., Smith J.A. et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc. Natl. Acad. Sci. USA. 86:1989;1836-1840.
128. Qian C., Li T., Shen T.Y., Libertine-Garahan L., Eckman J., Biftu T., Ip S. Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol. 250:1993;13-14.
129. Ramirez-Latorre J., Yu C.R., Qu X., Perin F., Karlin A., Role L. Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels. Nature. 380:1996;347-351.
130. Renko M., Quarto N., Morimoto T., Rifkin D.B. Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J. Cell. Physiol. 144:1990;108-114.
131. Revah F., Bertrand D., Galzi J.L., Devillers-Thiery A., Mulle C., Hussy N., Bertrand S., Ballivet M., Changeux J.P. Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature. 353:1991;846-849.
132. Rinne J.O., Myllykyla T., Lonnberg P., Marjamaki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 547:1991;167-170.
133. Role L.W. Diversity in primary structure and function of neuronal nicotinic acetylcholine receptor channels. Curr. Opin. Neurobiol. 2:1992;254-262.
134. Role L.W., Berg D.K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 16:1996;1077-1085.
135. Rowntree S., Kolb B. Blockade of basic fibroblast growth factor retards recovery from motor cortex injury in rats. Eur. J. Neurosci. 9:1997;2432-2441.
136. Rupniak N.M., Patel S., Marwood R., Webb J., Traynor J.R., Elliott J., Freedman S.B., Fletcher S.R., Hill R.G. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. Br. J. Pharmacol. 113:1994;1487-1493.
137. Sacaan A.I., Reid R.T., Santori E.M., Adams P., Correa L.D., Mahaffy L.S., Bleicher L., Cosford N.D., Stauderman K.A., McDonald I.A., Rao T.S., Lloyd G.K. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist. J. Pharmacol. Exp. Ther. 280:1997;373-383.
138. Sakaki T., Yamada K., Otsuki H., Yuguchi T., Kohmura E., Hayakawa T. Brief exposure to hypoxia induces bFGF mRNA and protein and protects rat cortical neurons from prolonged hypoxic stress. Neurosci. Res. 23:1995;289-296.
139. Schneider J.S., Tinker J.P., Van Velson M., Menzaghi F., Lloyd G.K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J. Pharmacol. Exp. Ther. 290:1999;731-739.
140. Schwartz R.D., Kellar K.J. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science. 220:1983;214-216.
141. Seguela P., Wadiche J., Dineley-Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 13:1993;596-604.
142. Semba J., Miyoshi R., Kito S. Nicotine protects against the dexamethasone potentiation of kainic acid- induced neurotoxicity in cultured hippocampal neurons. Brain Res. 735:1996;335-338.
143. Shahi G.S., Moochhala S.M. Smoking and Parkinson's disease - a new perspective. Rev. Environ. Health. 9:1991;123-136.
144. Shimohama S., Akaike A., Kimura J. Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation. Ann. NY Acad. Sci. 777:1996;356-361.
145. Shimohama S., Greenwald D.L., Shafron D.H., Akaika A., Maeda T., Kaneko S., Kimura J., Simpkins C.E., Day A.L., Meyer E.M. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res. 779:1998;359-363.
146. 3H]GABA uptake in nucleus basalis lesioned rats. Brain Res. 624:1993;295-298.
147. Socci D.J., Arendash G.W. Chronic nicotine treatment prevents neuronal loss in neocortex resulting from nucleus basalis lesions in young adult and aged rats. Mol. Chem. Neuropathol. 27:1996;285-305.
148. Sofroniew M.V., Galletly N.P., Isacson O., Svendsen C.N. Survival of adult basal forebrain cholinergic neurons after loss of target neurons. Science. 247:1990;338-342.
149. Stachowiak M.K., Moffett J., Joy A., Puchacz E., Florkiewicz R., Stachowiak E.K. Regulation of bFGF gene expression and subcellular distribution of bFGF protein in adrenal medullary cells. J. Cell Biol. 127:1994;203-223.
150. Stachowiak M.K., Moffett J., Maher P., Tucholski J., Stachowiak E.K. Growth factor regulation of cell growth and proliferation in the nervous system. A new intracrine nuclear mechanism. Mol. Neurobiol. 15:1997;257-283.
151. Sullivan J.P., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C.H., Adams P., Piattoni-Kaplan M., Buckley M.J. et al. Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 271:1994;624-631.
152. Sullivan J.P., Decker M.W., Donnelly-Roberts D., Brioni J.D., Bannon A.W., Holladay M.W., Anderson D.J., Briggs C.A., Williams M., Arneric S.P. Cholinergic channel activators: novel opportunities for the treatment of CNS
153. Takami K., Iwane M., Kiyota Y., Miyamoto M., Tsukuda R., Shiosaka S. Increase of basic fibroblast growth factor immunoreactivity and its mRNA level in rat brain following transient forebrain ischemia. Exp. Brain Res. 90:1992;1-10.
154. Terry A.V. Jr, Clarke M.S. Nicotine stimulation of nerve growth factor receptor expression. Life Sci. 55:1994;91-98.
155. Tooyama I., Kawamata T., Walker D., Yamada T., Hanai K., Kimura H., Iwane M., Igarashi K., McGeer E.G., McGeer P.L. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology. 43:1993;372-376.
156. Unsicker K., Reichert-Preibsch H., Schmidt R., Pettmann B., Labourdette G., Sensenbrenner M. Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons. Proc. Natl. Acad. Sci. USA. 84:1987;5459-5463.
157. Vernallis A.B., Conroy W.G., Berg D.K. Neurons assemble acetylcholine receptors with as many as three kinds of subunits while maintaining subunit segregation among receptor subtypes. Neuron. 10:1993;451-464.
158. Vernier J.M., El-Abdellaoui H., Holsenback H., Cosford N.D., Bleicher L., Barker G., Bontempi B., Chavez-Noriega L., Menzaghi F., Rao T.S., Reid R., Sacaan A.I., Suto C., Washburn M., Lloyd G.K., McDonald I.A. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 42:1999;1684-1686.
159. Vescovi A.L., Reynolds B.A., Fraser D.D., Weiss S. bFGF regulates the proliferative fate of unipotent (neuronal) and bipotent (neuronal/astroglial) EGF-generated CNS progenitor cells. Neuron. 11:1993;951-966.
160. Wada E., McKinnon D., Heinemann S., Patrick J., Swanson L.W. The distribution of mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene family (alpha 5) in the rat central nervous system. Brain Res. 526:1990;45-53.
161. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., Swanson L.W. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol. 284:1989;314-335.
162. Walicke P., Cowan W.M., Ueno N., Baird A., Guillemin R. Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension. Proc. Natl. Acad. Sci. USA. 83:1986;3012-3016.
163. Walicke P.A. Basic and acidic fibroblast growth factors have trophic effects on neurons from multiple CNS regions. J. Neurosci. 8:1988;2618-2627.
164. Wang F., Gerzanich V., Wells G.B., Anand R., Peng X., Keyser K., Lindstrom J. Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. J. Biol. Chem. 271:1996;17656-17665.
165. Warburton D.M., Wesnes K., Shergold K., James M. Facilitation of learning and state dependency with nicotine. Psychopharmacology (Berl.). 89:1986;55-59.
166. Ward C.D., Duvoisin R.C., Ince S.E., Nutt J.D., Eldridge R., Calne D.B. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology. 33:1983;815-824.
167. Warpman U., Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport. 6:1995;2419-2423.
168. 3H]nicotinic acetylcholine binding in Alzheimer's and Parkinson's disease: an autoradiographic study. Neurology. 38:1988;720-723.
169. Yamashita H., Nakamura S. Nicotine rescues PC12 cells from death induced by nerve growth factor deprivation. Neurosci. Lett. 213:1996;145-147.
170. Zoli M., Picciotto M.R., Ferrari R., Cocchi D., Changeux J.P. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J. 18:1999;1235-1244.